DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced that it recently completed shipment of its breakthrough Impella® 2.5 Cardiac Assist Device under 510(k) clearance to 100 U.S. hospitals. In June 2008, Abiomed received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Impella 2.5 device for partial circulatory support for periods up to six hours.
